MDGSW (Medigus) Accumulated Depreciation: $-0.45 Mil (As of Dec. 2024)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MDGSW Medigus Ltd MDGSW
12 GF Score
Price $0.02
! 6 Warning Signs
View Full Analysis

What is Medigus Accumulated Depreciation?

Medigus MDGSW 12 Accumulated Depreciation is $-0.45 Mil as of Dec. 2024. GuruFocus rates MDGSW with a GF Score™ of 12/100. The stock has 6 warning signs investors should review.

Note: A negative number here means the assets are depreciated. When depricates more, the absolute value gets bigger.

Medigus's quarterly accumulated depreciation declined from Dec. 2023 ($-0.38 Mil) to Jun. 2024 ($0.00 Mil) but then increased from Jun. 2024 ($0.00 Mil) to Dec. 2024 ($-0.45 Mil).

Medigus's annual accumulated depreciation declined from Dec. 2022 ($-2.20 Mil) to Dec. 2023 ($-0.38 Mil) but then increased from Dec. 2023 ($-0.38 Mil) to Dec. 2024 ($-0.45 Mil).

Medigus Accumulated Depreciation Related Terms

Medigus Accumulated Depreciation Historical Data

* Premium members only.

The historical data trend for Medigus's Accumulated Depreciation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Medigus Accumulated Depreciation Chart

Medigus Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Accumulated Depreciation
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.38 -1.33 -2.20 -0.38 -0.45

Medigus Semi-Annual Data
Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Accumulated Depreciation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.20 0.00 -0.38 0.00 -0.45
MDGSW
12GF Score
Medigus Ltd MDGSW
Accumulated Depreciation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Medigus Accumulated Depreciation Calculation

The cumulative depreciation of an asset up to a single point in its life. Regardless of the method used to calculate it, the depreciation of an asset during a single period is added to the previous period's accumulated depreciation to get the current accumulated depreciation.

What does a Accumulated Depreciation of $-0.45 Mil mean?
Medigus (MDGSW) has a Accumulated Depreciation of $-0.45 Mil as of Dec. 2024. Accumulated depreciation is a contra-asset item that accounts for the decline in value of long-term assets. View historical data on Medigus and its competitors.
Is Medigus' Accumulated Depreciation too high?
Medigus' current Accumulated Depreciation is $-0.45 Mil. Overall, Medigus has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Medigus' Accumulated Depreciation compare to RMSL and HSDT?
Medigus' Accumulated Depreciation of $-0.45 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accumulated Depreciation for a Medical Devices & Instruments company?
A good Accumulated Depreciation depends on the Medical Devices & Instruments industry context. However, Accumulated Depreciation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accumulated Depreciation mean?
A high Accumulated Depreciation can signal that a stock is expensive relative to its fundamentals. Accumulated depreciation is a contra-asset item that accounts for the decline in value of long-term assets. View historical data on Medigus and its competitors. Medigus's current Accumulated Depreciation is $-0.45 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medigus stock overvalued right now?
Medigus (MDGSW) has a current Accumulated Depreciation of $-0.45 Mil. The current Accumulated Depreciation is $-0.45 Mil. Medigus' overall GF Score™ is 12/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accumulated Depreciation calculated?
Accumulated Depreciation is calculated from a company's financial statements. For Medigus (MDGSW), the current Accumulated Depreciation is $-0.45 Mil as of Dec. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Medigus Business Description

Address 10 Hanechoshet Street, 4th Floor, Tel Aviv, ISR, 6971072
Xylo Technologies Ltd is an Israel-based medical device company. The company is engaged in the development, manufacturing, and marketing of direct vision systems for minimally invasive medical procedures and safety systems for drones and the electric vehicle (EV) sector. The key product of the company is the MUSE (Medigus Ultrasonic Surgical Endostapler) system is a single-use device for the incision-less treatment of GERD (gastroesophageal reflux disease), which is based on proprietary platform technology and know-how. The company operates in four segments are: Corporate, Online advertising & internet traffic routing, Online event management, real-estate and electronics. The company's geographical segments include USA, Europe, Great Britain, Israel, Canada, Asia and others.
12GF Score

Get the complete analysis for MDGSW

Accumulated Depreciation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.02
Price